Skip to Content


In the US, Nafarelin (nafarelin systemic) is a member of the drug class gonadotropin releasing hormones and is used to treat Endometriosis and Precocious Puberty.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Gonadotropin releasing hormone (GnRH) agonist

Chemical Name


Foreign Names

  • Nafarelinum (Latin)
  • Nafarelin (German)
  • Nafaréline (French)
  • Nafarelina (Spanish)

Generic Names

Brand Names

  • Nafarelil 0.2%
    Fuji Seiyaku, Japan
  • Nasanyl 0.2%
    Pfizer Japan, Japan
  • Synarel
    Farmagon, Norway; GD Searle, United States; Neolpharma, Israel; Pfizer, Australia; Pfizer, Canada; Pfizer, Czech Republic; Pfizer, France; Pfizer, United Kingdom; Pfizer, Ireland; Pfizer, Netherlands; Seid, Spain; Zodiac, Brazil
  • Synarela
    Pfizer, Germany; Pfizer, Denmark; Pfizer, Finland; Pfizer, Norway; Pfizer, Sweden; Pfizer ApS, Iceland
  • Synrelina
    Pfizer PFE, Switzerland


BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.